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LETTERS
Imported West Nile
Virus Infection in
Europe 
To the Editor: We report the case
of an 82-year-old man, recently
arrived in France from Atlanta,
Georgia, USA, who had chills and
fever in late August 2002. He left
Atlanta on August 26, 2002, and spent
a week in Paris before he reached
Burgundy. On day 9, after his arrival
in the town of Dijon, he had chills and
fever (40°C), weakness, malaise,
diarrhea, and headache. He was then
admitted to Dijon University
Hospital. Physical examination
indicated hyporeflexia, mild changes
in mental status, and no neck stiffness.
No lumbar puncture was performed.
Laboratory findings included the
following: hyponatremia, 129
mmol/L (normal range 135–145
mmol/L); C-reactive protein, 13 mg/L
(normal <3 mg/L); lymphocyte count,
500 cells/mm3 (normal range,
1,000–4,000 cells/mm3); positive
antinuclear antibodies, 1/160 (homog-
enous); and positive anti-DNA anti-
bodies, 76 Word Health Organization
(WHO) U (normal <39 WHO U).
Blood and urine samples remained
sterile. Results of the chest
roentgenogram and electrocardiogram
were normal.
Serum immunoglobulin (Ig) M
antibodies to West Nile virus (WNV)
were detected by using antibody-cap-
ture enzyme-linked immunosorbent
assay (ELISA); IgG antibodies were
not found by ELISA. A second sero-
logic test performed 2 weeks later in
the United States also showed specif-
ic IgM antibodies to WNV. The diag-
nosis of WNV infection was thus
established. Four days after admis-
sion, the patient no longer had a fever,
and his mental status was normal.
WNV infection is a potentially
lethal mosquito-borne infection (1).
Since 1994, many notable outbreaks
have occurred (2–4). The virus
emerged in New York, New York,
USA, in 1999, and WNV infection is
likely to become enzootic in the
United States (5). In 2002, WNV was
reported in 43 states, and human cases
were reported in 33 states (6). The
first human case in Georgia was
described in 2001.
We report the first imported case
of WNV infection in Europe, on the
basis of criteria established by the
Centers for Disease Control and
Prevention. WNV infection was sus-
pected because our patient arrived
from an area where WNV is epidemic
during the late summer. Clinical find-
ings were similar to those described in
previous cases (5). Encephalitis was
suspected because the patient showed
a reversible alteration of mental status
and headache. Although hyponatrem-
ia and lymphocytopenia have previ-
ously been reported in cases of WNV
infection, positive anti-DNA antibod-
ies is a finding of particular interest.
However, the mild elevation of anti-
body titers is common in other viral
infections, especially in those caused
by members of the Flaviviridae fami-
ly such as hepatitis C virus (7).
Although the prognosis of WNV
infection is generally poor in elderly
patients, our patient had a good out-
come (5,8).
In conclusion, physicians in west-
ern Europe should be aware of the risk
of WNV infection among travelers
from a disease-endemic area such as
the United States, especially during
late summer. Specific antibody detec-
tion tests should be performed in such
patients with unexplained fever, par-
ticularly when they show evidence of
neurologic disease. Suspected and
confirmed cases can then be quickly
reported to health departments, lead-
ing to an improvement in the public
health response. However, imported
cases like this one are not likely to
contribute to the spread of WNV
infection in Europe. Indeed, human
viremia levels seem too low and of
insufficient duration to allow the
infection of competent mosquito vec-
tors and the subsequent transmission
of the virus to other hosts, such as
horses or humans (9).
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